Results 151 to 160 of about 71,029 (345)

Stachydrine is effective and selective against blast phase chronic myeloid leukaemia through inhibition of multiple receptor tyrosine kinases [PDF]

, 2022
Ruixin Gu, Wei Zhang, Dandan Xu
openalex   +1 more source

Cytokine pathways driving diverse tissue pathologies in rheumatoid arthritis

Arthritis &Rheumatology, Accepted Article.
Rheumatoid arthritis is a complex systemic disorder characterised primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease e.g. of the lung with potentially devastating clinical consequences.
Aurelie Najm, Lyn D. Ferguson, Iain B. McInnes   +2 more
wiley   +1 more source

Analysis of the transcriptome for novel therapeutic targets, and investigation of the role of APOBEC3B in chronic myeloid leukaemia stem cells

, 2018
Lorna Jackson
openalex   +1 more source

Dysregulation of U12‐Type Splicing in Lupus Neutrophils

Arthritis &Rheumatology, Accepted Article.
Abstract. Objective Neutrophil dysfunction is a hallmark of systemic lupus erythematosus (SLE), but its molecular basis remains unclear. This study explores transcriptional and post‐transcriptional changes in low‐density granulocytes (LDGs), a proinflammatory neutrophil subset expanded in SLE, focusing on NADPH oxidase (Nox) function and minor intron ...
Luz P. Blanco, Binod Regmi, Carmelo Carmona‐Rivera, Yudong Liu, Xiantao Wang, Philip M. Carlucci, Monica M. Jackson, Zerai Manna, Sarfaraz Hasni, Markus Hafner, Hong‐Wei Sun, Mariana J. Kaplan   +11 more
wiley   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

CHRONIC MYELOID LEUKAEMIA: EPIDEMIOLOGY DATA (2002–2007)

Zdravniški Vestnik, 2008
BACKGROUND Chronic myeloid leukaemia (CML) is a rare clonal neoplastic disease of hematopoieticstem cells. Epidemiology data of CML patients in Slovenia are presented.
Irena Preložnik Zupan, Tadej Pajič, Marjana Glaser, Tatjana Grmek Zemljič, Mateja Grat, Nataša Fikfak, Irena Bricman, Marija Čeh, Vlasta Petric   +8 more
doaj  

T315I – a gatekeeper point mutation and its impact on the prognosis of chronic myeloid leukemia

Advances in Laboratory Medicine
BCR-ABL kinase domain mutations are an important cause of resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukaemia (CML) of which T315I is the most treatment-resilient. This study aimed to observe the frequency of T315I and its impact
Kaleem Bushra, Shahab Sadaf, Shamsi Tahir Sultan   +2 more
doaj   +1 more source

Chronic Myeloid Leukaemia and Pregnancy [PDF]

BMJ, 1950
L M, EDWARDS, H D, FREETH
openaire   +2 more sources

Cold atmospheric plasma‐mediated tumor microenvironment remodeling for cancer treatment

BMEMat, EarlyView.
Schematic presentation of CAP‐mediated TME remodeling. This review summarizes recent efforts in cold atmospheric plasma (CAP) application in cancer treatment, highlighting the anticancer potential of CAP, molecular mechanisms, and future perspectives for further improvement and clinical translation.
Israr Khan, Qiujie Fang, Cao Fei, Ziyuan Wang, Zhaowei Chen, Guojun Chen, Zhiming Xu, Shu Xu, Zhitong Chen   +8 more
wiley   +1 more source

Resistant Bilateral Chylous Effusion as a Late Adverse Effect of Dasatinib Treatment in Chronic Myeloid Leukaemia [PDF]

, 2019
Emine Zengin, Nazan Sarper, Sema Aylan Gelen, Salih Topçu   +3 more
openalex   +1 more source